Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · IEX Real-Time Price · USD
1.840
-0.100 (-5.15%)
At close: Jul 19, 2024, 4:00 PM
1.790
-0.050 (-2.72%)
Pre-market: Jul 20, 2024, 9:28 AM EDT

Cognition Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Selling, General & Admin
13.5313.5313.2310.034.523.45
Research & Development
42.3237.230.3218.5712.8914.38
Operating Expenses
55.8550.7243.5528.617.4117.83
Operating Income
-55.85-50.72-43.55-28.6-17.41-17.83
Interest Expense / Income
0.030.030.030.891.751.02
Other Expense / Income
-27.11-24.96-22.18-17.78-11.32-14.01
Pretax Income
-28.77-25.79-21.4-11.72-7.84-4.84
Net Income
-28.77-25.79-21.4-11.72-7.84-4.84
Preferred Dividends
0004.534.233.92
Net Income Common
-28.77-25.79-21.4-16.25-12.07-8.76
Shares Outstanding (Basic)
343024512
Shares Outstanding (Diluted)
343024512
Shares Change
15.95%27.03%355.42%921.60%-66.56%-
EPS (Basic)
-0.92-0.86-0.91-3.13-23.76-5.77
EPS (Diluted)
-0.92-0.86-0.91-3.13-23.76-5.77
Free Cash Flow
-20.66-16.17-18.7-3.66-3.44-3.24
Free Cash Flow Per Share
-0.61-0.54-0.79-0.70-6.78-2.13
EBITDA
-28.49-25.51-21.13-10.73-5.99-3.74
Depreciation & Amortization
0.250.250.240.090.10.08
EBIT
-28.74-25.76-21.37-10.82-6.09-3.82
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).